Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
Status:
Terminated
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
Vorinostat (Suberoylanilide Hydroxamic Acid; NSC 701852) is a drug that inhibits an enzyme
that plays a key role in the regulation of cell survival, growth, and eventual cell death,
all of which play a role in cancer. As a result, this drug has the potential to affect a
tumor's ability to survive. Vorinostat is the most potent drug of its kind that is currently
under investigation in clinical trials. The primary objective of this study is to define the
maximum safest dose of vorinostat in combination with a standard chemotherapy agent,
docetaxel, in patients with advanced and relapsed lung, bladder, or prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center